RxDoctor Payments Data

Mobin Ghavami, MD

Internal Medicine · Lodi, CANPI 1447239744

Payments from drug & device makers

$14,316in general payments, 2019–2025

Across 589 payments — averaging $24.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Forte Bio-pharma LLC$4K
  • AstraZeneca$2K
  • AbbVie$940
  • Boehringer Ingelheim$866
  • Lilly USA, LLC$741
  • Novo Nordisk$733
  • plus $5K from 33 others

What the payments were for

  • Food & beverage$14,316100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,316 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$215,253
Medicare patients
417
Services billed
5,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin167$143,048
OzempicSemaglutide147$138,150
Enbrel SureclickEtanercept12$78,094
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$69,349
LinzessLinaclotide88$55,693
JanuviaSitagliptin Phosphate66$52,445
FarxigaDapagliflozin Propanediol54$48,373
EliquisApixaban58$47,548
Janumet XrSitagliptin Phos/Metformin Hcl51$38,504
RybelsusSemaglutide27$34,032
XareltoRivaroxaban34$27,845
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate116$20,160
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$19,208
Albuterol Sulfate HfaAlbuterol Sulfate566$18,612
Tresiba Flextouch U-200Insulin Degludec61$17,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$733$172,182174 claims
Boehringer IngelheimJardiance, Spiriva Respimat$866$150,103181 claims
MerckJanuvia, Janumet Xr$76$90,948117 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,051$78,841128 claims
GSKTrelegy Ellipta$177$69,349104 claims
AbbVieLinzess$940$55,69388 claims
PfizerEliquis$548$47,54858 claims
Johnson & JohnsonXarelto$306$27,84534 claims
Lilly USA, LLCMounjaro$741$15,96916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Lodi

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →